Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

Peter Martin, MD
Published: Monday, May 22, 2017



Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

Right now, for those patients who can tolerate intensive therapy who want a very long remission duration or long treatment-free interval, high-dose cytarabine followed by autologous transplant is likely the best way to achieve that, Martin explains.

There is clearly a group of patients who should undergo transplant, but there are also many patients who can have very good outcomes without transplant. However, the difference between the 2 groups is that the latter will likely need to be administered more therapies during what would be a treatment-free interval.
 


Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).

Right now, for those patients who can tolerate intensive therapy who want a very long remission duration or long treatment-free interval, high-dose cytarabine followed by autologous transplant is likely the best way to achieve that, Martin explains.

There is clearly a group of patients who should undergo transplant, but there are also many patients who can have very good outcomes without transplant. However, the difference between the 2 groups is that the latter will likely need to be administered more therapies during what would be a treatment-free interval.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x